Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Aug 30 2024

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for its Scopolamine Transdermal System. This product is designed to prevent nausea and vomiting related to anesthesia, narcotic pain medications, and motion sickness. The approval marks the fifth ANDA approval for Zydus in its transdermal portfolio, showcasing its manufacturing capabilities in complex drug delivery systems. The Scopolamine Transdermal System will be produced at Zydus's facility in Ahmedabad.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases